Proteinase K Global Market Report 2024

The proteinase k market has grown rapidly in recent years. It will grow from $4.47 billion in 2023 to $4.92 billion in 2024 at a compound annual growth rate (CAGR) of 10.0%. The growth observed in the historical period can be attributed to the expansion of biotechnology and life sciences research, advancements in diagnostic testing, the evolving requirements of pharmaceutical development, increased demand for bioprocessing and protein purification, and the growing emphasis on quality control in the food and beverages industry.

The proteinase k market is expected to see rapid growth in the next few years. It will grow to $7.22 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. The anticipated growth in the forecast period can be attributed to the sustained expansion of molecular diagnostics, ongoing advancements in precision medicine, the increasing scale of biopharmaceutical manufacturing, research progress in proteomics and genomics, and the rising applications in forensic sciences. Noteworthy trends expected in the forecast period encompass the growth of the pharmaceutical industry, continuous technological advancements, intensified market competition and pricing dynamics, a focus on sustainable and animal-free variants, as well as the impact of global pandemics on the market landscape.

The anticipated growth of the proteinase K market is expected to be driven by the increasing prevalence of chronic diseases. Chronic diseases, lasting more than a year and requiring continuous medical treatment, are a significant target for proteinase K usage. The enzyme plays a crucial role in both preventative and therapeutic applications, facilitating the extraction and isolation of DNA and RNA from viruses associated with various chronic diseases. For instance, data from the National Library of Medicine in January 2023 projected a rise in the number of individuals aged 50 and older with at least one chronic condition in the US, reaching 142.66 million by 2050. This underscores the growing significance of proteinase K in addressing the needs of a population grappling with chronic diseases.

The increasing incidence of infectious diseases, particularly tuberculosis, is poised to contribute to the growth of the proteinase K market. Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, is a global health concern, and proteinase K finds application in TB research by enabling the extraction and isolation of DNA and RNA from the bacterium. Notably, the World Health Organization reported a 4.5% increase in tuberculosis cases in 2021. This highlights the vital role of proteinase K in addressing the rising challenges posed by infectious diseases, further substantiating its market growth potential.

The proteinase K market is witnessing a notable trend towards product innovation, with major companies actively launching novel products to strengthen their positions. One such example is Biocatalysts Ltd., a UK-based biotechnology company, which introduced Proteocut K. This high-quality and cost-effective alternative to liquid proteinase K is a subtilisin-type serine protease with broad substrate specificity, suitable for a variety of life science applications. Its efficient hydrolysis of various proteins is attributed to its broad pH profile (6.0 - 10.0) and temperature range (40 -70°C). This innovative offering enhances the choices available in the proteinase K market, providing users with a versatile enzyme solution.

Companies are focused on continuous product development to stay competitive. ArcticZymes Technologies ASA, a Norway-based biotechnology company, exemplifies this by upscaling production and launching a glycerol-free version of ArcticZymes Proteinase. Known for its high activity and stability, this enzyme is valuable in molecular biology protocols, diagnostics, and bioprocessing. The glycerol-free variant offers enhanced stability at -20°C for up to one year, making it suitable for lyophilization and automated processes.

In January 2023, Lighthouse Pharma, a US-based biopharmaceutical company, acquired the small molecule proteinase inhibitor portfolio from Quince Therapeutics Inc. This acquisition positions Lighthouse Pharma to advance the development of gingipain inhibitors for dementia and other disorders, offering innovative treatment options. Quince Therapeutics Inc., a US-based biotechnology company specializing in proteinase inhibitors, contributes valuable assets to Lighthouse Pharma's research and development efforts.

Major companies operating in the proteinase k market report are Merck KGaA, QIAGEN NV, Thermo Fisher Scientific Inc., F Hoffmann-La Roche Ltd., Worthington Biochemical Corporation, Sigma-Aldrich Co. LLC, Behemoth Inteligencia para os Negocios LTDA, Codexis Inc., Beijing SBS Genetech Co. Ltd., Hoffmann-La Roche Ltd., Amicogen Inc., Amano Enzyme Inc., Sisco Research Laboratories Pvt. Ltd., Promega Corporation, Bioline Diagnostics LLP, Biocompare, BioVision Inc., Creative Enzymes, G-Biosciences, Advanced Enzymes Technologies, Cell Signaling Technology Inc., Dyadic International, Amresco LLC, Abcam plc, Bio Basic Inc., BioChain Institute Inc., BioLegend Inc., Bio-Rad Laboratories Inc., Enzo Life Sciences Inc., GenScript Biotech Corporation.

North America was the largest region in the global proteinase k market in 2023. Asia-Pacific is expected to be the fastest-growing region in the global proteinase k market during the forecast period. The regions covered in the proteinase k market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the proteinase k market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The lyophilized powder form is obtained through a dehydration process involving freezing and vacuum removal of water. Proteinase K finds applications across various therapeutic areas such as infectious diseases, diabetes, oncology, cardiology, nephrology, autoimmune diseases, and neurology. Its uses extend to isolation and purification of genomic DNA and RNA, in situ hybridization, mitochondria isolation, and enzyme removal.Target customers for Proteinase K include contract research organizations, academic institutes, biotechnology companies, and diagnostics laboratories. Its role in facilitating the efficient processing of samples makes it a key component in research and diagnostic workflows within the specified industries and applications.

The proteinase k market research report provides proteinase k market statistics, including proteinase k industry global market size, regional shares, competitors with a proteinase k market share, detailed proteinase k market segments, market trends and opportunities, and any further data you may need to thrive in the proteinase k industry. This proteinase k market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The proteinase K market consists of sales of acid proteinase, neutral proteinase, and alkaline proteinase. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.